MetaVia Inc.
MTVA
Clasificación en acciones
#32618
Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a... Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). This follows the successful completion of Phase 1 trials for type 2 diabetes mellitus (T2DM), and the compound holds promise for use as both a standalone therapy and in combination treatments. Another significant asset, DA-1726, an innovative oxyntomodulin analogue that functions as a dual agonist for GLP-1 and glucagon receptors, is presently in preclinical development specifically for treating obesity. MetaVia's broader therapeutic pipeline also includes ANA001, a distinct oral niclosamide formulation intended for moderate COVID-19 patients; NB-01, designed to address painful diabetic neuropathy; NB-02, targeting cognitive impairment; and Gemcabene, for the management of dyslipidemia. The company engages in strategic partnerships, notably a licensing agreement with Pfizer Inc. for the research, development, manufacturing, and commercialization of Gemcabene. Additionally, a joint research collaboration with Dong-A ST and ImmunoForge supports the advancement of DA-1726. The entity adopted its current name, MetaVia Inc., in November 2024, transitioning from its former identity as NeuroBo Pharmaceuticals, Inc.
Precio por acción
$1.40
Capitalización bursátil
$9.22M
Cambio (1 día)
4.48%
Cambio (1 año)
-14.11%
País
US
Comercio MetaVia Inc. (MTVA)
Categoría
Healthcare
Historial del precio de la acción de MetaVia Inc. (MTVA)
Precio más alto de cierre: $2.19 el 2024-12-01
Precio más bajo de cierre: $60.07K el 2016-08-01
Precio más bajo de cierre: $60.07K el 2016-08-01
Historial del precio de la acción de MetaVia Inc. desde 2016 hasta 2026
Desempeño anual del precio de la acción
| Año | Rendimiento |
|---|---|
| 2024 | -41.80% |
| 2023 | -64.19% |
| 2022 | -96.91% |
| 2021 | -75.22% |
| 2020 | -26.05% |
| 2019 | -64.56% |
| 2018 | -89.12% |
| 2017 | -4.63% |
| 2016 | 0.00% |
Precio de la acción de empresas similares o competidoras
| Empresa | Precio de la acción | Cambio 1a% | País |
|---|---|---|---|
| $532.09 | 24.77% |
US
|
|
| $236.63 | 781.30% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $889.94 | 9.31% |
NL
|
|
| $291.42 | 2.39% |
BE
|
